Dolutegravir/abacavir/lamivudine (Triumeq®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000595
English
Authors' recommendations:
Dolutegravir/abacavir/lamivudine (Triumeq®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2365
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Adult
- Cross-Over Studies
- Dietary Fats
- Drug Therapy, Combination
- Female
- Food-Drug Interactions
- Male
- Therapeutic Equivalency
- Vaginal Creams, Foams, and Jellies
- Young Adult
- HIV Infections
- HIV
- Anti-HIV Agents
- Dideoxynucleosides
- Heterocyclic Compounds, 3-Ring
- Lamivudine
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.